74 related articles for article (PubMed ID: 29607903)
1. Effects of the Chemical Structures of Oligoarginines Conjugated to Biocompatible Polymers as a Mucosal Adjuvant on Antibody Induction in Nasal Cavities.
Mohri K; Miyata K; Egawa T; Tanishita S; Endo R; Yagi H; Ukawa M; Ochiai K; Hiwatari KI; Tsubaki K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Chem Pharm Bull (Tokyo); 2018; 66(4):375-381. PubMed ID: 29607903
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
Ukawa M; Tanishita S; Yagi H; Yoshida Y; Tomono T; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Mol Pharm; 2019 Mar; 16(3):1105-1118. PubMed ID: 30715891
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of d-Octaarginine-Linked Polymers as Promising Adjuvants for Mucosal Vaccination through Influenza Virus Challenge.
Miyata K; Mohri K; Egawa T; Endo R; Morimoto N; Ochiai K; Hiwatari K; Tsubaki K; Tobita E; Uto T; Baba M; Sakuma S
Bioconjug Chem; 2016 Aug; 27(8):1865-71. PubMed ID: 27463562
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity of immunoglobulin A secreted on the nasal mucosa in mice nasally inoculated with inactivated H1N1 influenza A viruses in the presence of D-octaarginine-linked polymers.
Sakuma S; Morimoto N; Nishida K; Murakami T; Egawa T; Endo R; Kataoka M; Yamashita S; Miyata K; Mohri K; Ochiai K; Hiwatari K; Koike S; Tobita E; Uto T; Baba M
Eur J Pharm Biopharm; 2015 May; 92():56-64. PubMed ID: 25720816
[TBL] [Abstract][Full Text] [Related]
5. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
6. Oligoarginine-linked polymers as a new class of penetration enhancers.
Sakuma S; Suita M; Masaoka Y; Kataoka M; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Yamashita S
J Control Release; 2010 Dec; 148(2):187-96. PubMed ID: 20800631
[TBL] [Abstract][Full Text] [Related]
7. Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses.
Tanishita S; Ukawa M; Tomono T; Yoshida Y; Tsujioka T; Miyata K; Tobita E; Uto T; Baba M; Sakuma S
Bioconjug Chem; 2019 Dec; 30(12):3028-3037. PubMed ID: 31738536
[TBL] [Abstract][Full Text] [Related]
8. Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms.
Ukawa M; Endo R; Yagi H; Tomono T; Miyata K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Int J Pharm; 2022 Feb; 613():121376. PubMed ID: 34915143
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
[TBL] [Abstract][Full Text] [Related]
11. Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
Miyata K; Ukawa M; Mohri K; Fujii K; Yamada M; Tanishita S; Higashitarumi S; Ishizaki S; Kumagai H; Ochiai K; Hiwatari KI; Tsubaki K; Shigeno K; Tobita E; Kobayashi H; Sakuma S
Bioconjug Chem; 2018 May; 29(5):1748-1755. PubMed ID: 29648441
[TBL] [Abstract][Full Text] [Related]
12. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
13. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
Moriyama M; Chino S; Ichinohe T
Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
15. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
16. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
Tomono T; Yagi H; Ukawa M; Ishizaki S; Miwa T; Nonomura M; Igi R; Kumagai H; Miyata K; Tobita E; Kobayashi H; Sakuma S
Eur J Pharm Biopharm; 2020 Sep; 154():186-194. PubMed ID: 32681963
[TBL] [Abstract][Full Text] [Related]
17. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
18. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748
[TBL] [Abstract][Full Text] [Related]
19. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
